/
BIAF
$0.80-$0.03 (-3.18%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$5.2M
6M shares
52-week range
$0.69 – $13.50
1% from low
Sector
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NASDAQ
CS
Borrow rate
63.95%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-248.20
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $4.8K | $2.5M | $9.4M | $6.2M |
| Cost of revenue | $40.3K | $22.2K | $4.8K | $467 | $1.7M | $6.0M | $4.7M |
| Gross profit | −$40.3K | −$22.2K | −$4.8K | $4.3K | $791.6K | $3.4M | $1.4M |
| Gross margin | — | — | — | 90.3% | 31.3% | 36.1% | 23.2% |
| R&D | $1.9M | $1.6M | $1.1M | $1.5M | $1.7M | $1.8M | $2.1M |
| Operating income | −$3.1M | −$2.6M | −$2.2M | −$4.0M | −$8.0M | −$9.0M | −$10.6M |
| EBITDA | −$3.0M | −$6.9M | −$5.3M | −$5.6M | −$7.6M | −$8.3M | −$14.3M |
| Net income | −$3.3M | −$7.3M | −$6.3M | −$8.2M | −$7.9M | −$9.0M | −$14.9M |
| Net margin | — | — | — | -169771.2% | -313.5% | -96.6% | -242.0% |
| EPS (diluted) | -13.50 | -29.70 | -69.57 | -54.30 | -27.30 | -22.50 | -8.66 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $7M | $-8.10 | $-8.10–$-8.10 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
bioAffinity Technologies, Inc. Common Stock
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
www.bioaffinitytech.com- Employees
- 57
- IPO / List date
- Sep 1, 2022
- HQ
- SAN ANTONIO, TX
Held by traders on TradeandTell
No one on the platform currently holds BIAF.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in BIAF as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-09-19 | 1-for-30reverse |
Recent trades on TradeandTell
No one on the platform has traded BIAF yet.
